Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
E-pub ahead of print

Short and long-term effectiveness and safety of vedolizumab in treatment-refractory patients with ulcerative colitis and Crohn's disease - a real-world two-center cohort study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. The prevention and management of Crohn's disease postoperative recurrence: results from the Y-ECCO/ClinCom 2019 Survey

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Enhanced processing of von Willebrand factor reflects disease severity and discriminates severe portal hypertension in cirrhosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Challenges and obstacles in the transition process through the eyes of the gastroenterologist

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Vitamin D deficiency in a European inflammatory bowel disease inception cohort: an Epi-IBD study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. ECCO topical review: Refractory Inflammatory Bowel Disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Progressive alcohol-related liver fibrosis is characterised by imbalanced collagen formation and degradation

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVES: Real-world data about sustained clinical remission (SCR) and treatment optimization with vedolizumab for ulcerative colitis (UC) and Crohn's disease (CD) are scarce. We aimed to investigate the short and long-term effectiveness and safety of vedolizumab in a real-world cohort in Denmark.

METHODS: A retrospective two-center cohort study was conducted between November 2014 and November 2019 with the primary outcomes of clinical remission (CR) at weeks 14, 30, 52 and 104 and SCR defined as CR at week 14 through week 52.

RESULTS: The study included 182 patients (UC: 97, CD: 85), all previously exposed to at least one biological therapy. Rates of CR at weeks 14, 30, 52 and 104 were 36.6, 35.1, 34.0 and 27.8%, respectively, in UC, and 31.7, 30.1, 26.5 and 22.4% in CD. SCR was achieved in 19.6 and 20.0%, respectively. In UC and CD, optional dosing of vedolizumab at week 10 (odds ratio [OR] = 0.23 (95% confidence interval [CI], 0.03-1.17), and OR = 0.68 (95% CI, 0.22-2.04)), as well as increase of frequency (OR = .26 (95% CI, 0.01-2.86), and OR = 0.19 (95% CI, 0.01-1.45)), were not associated with CR at week 52. Furthermore, combination treatment with azathioprine was not associated with long-term outcomes. However, dose intensification of vedolizumab successfully restored CR in 65.2 and 57.1% of patients with UC and CD experiencing loss of response.

CONCLUSIONS: Vedolizumab is effective in achieving and restoring short and long-term CR and SCR in patients with treatment-refractory UC and CD. This study emphasizes that supplementary dosing at week 10, and simultaneous treatment with azathioprine, did not improve long-term outcomes.

Original languageEnglish
JournalEuropean journal of gastroenterology & hepatology
ISSN0954-691X
DOIs
Publication statusE-pub ahead of print - 7 Jun 2021

ID: 66134460